Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Total Debt (2024 - 2026)

Nuvation Bio has reported Total Debt over the past 3 years, most recently at $53.1 million for Q1 2026.

  • Quarterly Total Debt rose 834.34% to $53.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $53.1 million through Mar 2026, up 834.34% year-over-year, with the annual reading at $52.9 million for FY2025, 742.46% up from the prior year.
  • Total Debt was $53.1 million for Q1 2026 at Nuvation Bio, roughly flat from $52.9 million in the prior quarter.
  • Over five years, Total Debt peaked at $53.1 million in Q1 2026 and troughed at $5.7 million in Q1 2025.
  • The 3-year median for Total Debt is $32.1 million (2024), against an average of $30.4 million.
  • Year-over-year, Total Debt skyrocketed 351.75% in 2025 and then skyrocketed 834.34% in 2026.
  • A 3-year view of Total Debt shows it stood at $6.3 million in 2024, then skyrocketed by 742.46% to $52.9 million in 2025, then grew by 0.35% to $53.1 million in 2026.
  • Per Business Quant, the three most recent readings for NUVB's Total Debt are $53.1 million (Q1 2026), $52.9 million (Q4 2025), and $52.7 million (Q3 2025).